Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Rhea-AI Summary

Halozyme (NASDAQ: HALO) will report its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, released after the close of trading.

According to the company, a conference call to discuss results will be held on February 17, 2026 at 1:30pm PT / 4:30pm ET, with live webcast and replay available via Halozyme's Investors website.

News Market Reaction – HALO

-0.89%

1 alert

-0.89% News Effect

On the day this news was published, HALO declined 0.89%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings release date: February 17, 2026 Conference call time: 1:30pm PT / 4:30pm ET

2 metrics

Earnings release date February 17, 2026 Scheduled fourth quarter and full-year 2025 results release

Conference call time 1:30pm PT / 4:30pm ET Time for results conference call on February 17, 2026

Market Reality Check

Price: $67.37 Vol: Volume 1,642,712 is sligh...

normal vol

$67.37 Last Close

Volume Volume 1,642,712 is slightly below the 20-day average of 1,795,819 (relative volume 0.91x). normal

Technical Shares at 80.48, trading above the 200-day MA of 65.16 and within 2% of the 52-week high 82.22.

Peers on Argus

HALO slipped 0.92% while close peers were mixed: MRNA +2.14%, ROIV +5.01%, MDGL ...

HALO slipped 0.92% while close peers were mixed: MRNA +2.14%, ROIV +5.01%, MDGL +2.23%, VRNA +0.06%, RVMD -0.54%, pointing to stock-specific trading rather than a sector rotation.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Guidance raised	Positive	+3.7%	Raised 2025 estimates and 2026 multi-year financial guidance with higher revenue.
Jan 20	Investor call set	Positive	+1.8%	Scheduled call to present preliminary 2025 revenue and extended 2026–2028 guidance.
Jan 08	New Takeda deal	Positive	-4.0%	Global ENHANZE® collaboration and license for vedolizumab with potential royalties.
Dec 18	FDA approval	Positive	-1.0%	FDA approved RYBREVANT FASPRO™ with ENHANZE® for EGFR-mutated NSCLC.
Dec 08	Board change	Neutral	-1.6%	Election of Jim Lang to the board, adding healthcare and analytics experience.

Pattern Detected

Recent news shows mixed reactions: guidance raises drew positive moves, while partnership and FDA approval headlines saw modest selling pressure.

Recent Company History

Over the past few months, Halozyme issued several material updates, including raised 2025–2026 revenue and EPS guidance, a new Takeda ENHANZE® collaboration, and an FDA approval for RYBREVANT FASPRO™ with ENHANZE® on Dec 18, 2025. Some positive commercial and regulatory milestones were followed by negative price reactions, while financial guidance updates on Jan 20 and Jan 28, 2026 coincided with gains. Today’s earnings-date announcement fits into this cadence of scheduled investor communications.

Market Pulse Summary

This announcement schedules Halozyme’s fourth quarter and full-year 2025 results release and a confe...

Analysis

This announcement schedules Halozyme’s fourth quarter and full-year 2025 results release and a conference call on February 17, 2026. It follows recent guidance updates and business developments, including raised revenue outlooks and new ENHANZE® collaborations. Investors would usually focus on how reported royalty, product, and collaboration revenues compare with preliminary figures, as well as any revisions to multi-year guidance and balance sheet developments from recent financing and credit actions.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading.

Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^® and XYOSTED^®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2025-financial-and-operating-results-302684270.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme (HALO) release Q4 and full year 2025 results?

Halozyme will release Q4 and full year 2025 results on February 17, 2026 after market close. According to the company, the announcement will be followed by a conference call the same day to discuss financial and operating results.

How can investors join the Halozyme (HALO) February 17, 2026 conference call?

Investors can join the Halozyme conference call by pre-registering for the live webcast link provided by the company. According to the company, the call will be accessible via pre-registration and the Investors section on Halozyme's website for live and replay access.

What time is the Halozyme (HALO) earnings call on February 17, 2026?

The Halozyme earnings call is scheduled for 1:30pm PT / 4:30pm ET on February 17, 2026. According to the company, the call will discuss the fourth quarter and full year 2025 financial and operating results and will be webcast live.

Where will the Halozyme (HALO) earnings webcast and replay be available?

The live webcast and replay will be available in the Halozyme Investors section on the company's website. According to the company, both live access and a later replay will be posted on Halozyme's investor relations web pages for on-demand listening.

Will Halozyme (HALO) discuss operating as well as financial results on the February 17 call?

Yes, Halozyme will discuss both fourth quarter and full year 2025 financial and operating results on the call. According to the company, the conference call is intended to cover financial outcomes and related operating developments for 2025.